Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 28 versus NORINYL 1 80 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 28 versus NORINYL 1 80 28 DAY.
ENPRESSE-28 vs NORINYL 1+80 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive